Pfizer (PFE) to Discontinue Bococizumab Development Program; Sees EPS Impact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
November 1, 2016 6:30 AM EDTCompany will record a charge to GAAP and Adjusted earnings in the fourth quarter of 2016 estimated to be approximately $0.04 per share
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders. As a result, Pfizer has decided to discontinue the development... More
